ArticleMaterials (Basel, Switzerland)2025
NIR-Responsive Microbubble Delivery Platforms for Controlled Drug Release in Cancer Therapy.
Article in Materials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advanced Nanomaterials for Biological, Medical, and Environmental Applications: Current Progress and Future Perspectives.Materials (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer remains one of the leading causes of death worldwide. Therefore, the continuous development of effective therapeutic strategies is necessary. Conventional anticancer chemotherapy has low bioavailability and poor systemic distribution, resulting in serious side effects and limited therapeutic efficacy. To address these limitations, drug delivery systems that respond to external stimuli have been developed to release drugs at specific sites. In this study, a phase transition-based bubble-mediated emulsion system was developed to enable near-infrared (NIR)-induced drug release. This system consists of an oil phase, 2H,3H-perfluoropentane (PFC), a fluorinated liquid gas that evaporates at a certain temperature, and encapsulated IR-780 and paclitaxel to maintain stable microbubbles. Under NIR irradiation, IR-780 exhibits a photothermal conversion effect, which increases the temperature. Above the critical temperature, PFC undergoes a phase transition into gas, forming gas bubbles. This phase transition leads to a rapid volume expansion, destroys the microbubble structure, and triggers drug release. The NIR-responsive microbubble system developed in this study facilitated targeted and selective drug release through precise temperature control using the photothermal effects and phase transition. This system provides a novel platform to improve the efficacy of cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.